The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082)
Open Access
- 1 May 1993
- journal article
- clinical trial
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 168 (5), 1510-1516
- https://doi.org/10.1016/s0002-9378(11)90791-1
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virusThe Journal of Pediatrics, 1993
- Postexposure Prophylaxis with Zidovudine Suppresses Human Immunodeficiency Virus Type 1 Infection in SCID-hu Mice in a Time-Dependent MannerThe Journal of Infectious Diseases, 1991
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patientsThe Journal of Pediatrics, 1990
- Transfer of Zidovudine (AZT) by Human PlacentaThe Journal of Infectious Diseases, 1990
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Retroviruses and Mouse Embryos: A Rapid Model for Neurovirulence and Transplacental Antiviral TherapyScience, 1987
- Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseasesClinical Pharmacology & Therapeutics, 1987
- Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidineNature, 1986